{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T11:15:29Z","timestamp":1776856529139,"version":"3.51.2"},"reference-count":171,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T00:00:00Z","timestamp":1579651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Microorganisms"],"abstract":"<jats:p>Candida albicans represents the most frequent isolated yeast from bloodstream infections. Despite the remarkable progress in diagnostic and therapeutic approaches, these infections continue to be a critical challenge in intensive care units worldwide. The economic cost of bloodstream fungal infections and its associated mortality, especially in debilitated patients, remains unacceptably high. Candida albicans is a highly adaptable microorganism, being able to develop resistance following prolonged exposure to antifungals. Formation of biofilms, which diminish the accessibility of the antifungal, selection of spontaneous mutations that increase expression or decreased susceptibility of the target, altered chromosome abnormalities, overexpression of multidrug efflux pumps and the ability to escape host immune defenses are some of the factors that can contribute to antifungal tolerance and resistance. The knowledge of the antifungal resistance mechanisms can allow the design of alternative therapeutically options in order to modulate or revert the resistance. We have focused this review on the main factors that are involved in antifungal resistance and tolerance in patients with C. albicans bloodstream infections.<\/jats:p>","DOI":"10.3390\/microorganisms8020154","type":"journal-article","created":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T11:17:57Z","timestamp":1579691877000},"page":"154","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":184,"title":["Candida albicans Antifungal Resistance and Tolerance in Bloodstream Infections: The Triad Yeast-Host-Antifungal"],"prefix":"10.3390","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2899-6615","authenticated-orcid":false,"given":"Sofia","family":"Costa-de-Oliveira","sequence":"first","affiliation":[{"name":"Division of Microbiology, Department of Pathology, Faculty of Medicine, University of Porto, Al. Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"},{"name":"Center for Research in Health Technologies and Information Systems (CINTESIS), R. Dr. Pl\u00e1cido da Costa, 4200-450 Porto, Portugal"}]},{"given":"Ac\u00e1cio G.","family":"Rodrigues","sequence":"additional","affiliation":[{"name":"Division of Microbiology, Department of Pathology, Faculty of Medicine, University of Porto, Al. Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"},{"name":"Center for Research in Health Technologies and Information Systems (CINTESIS), R. Dr. Pl\u00e1cido da Costa, 4200-450 Porto, Portugal"},{"name":"Burn Unit, S\u00e3o Jo\u00e3o Hospital Center, Al. Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2020,1,22]]},"reference":[{"key":"ref_1","unstructured":"Calderone, R. (2002). Candida and Candidiasis, ASM Press."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1177\/00220345950740050301","article-title":"Oral Candida: Clearance, colonization, or candidiasis?","volume":"74","author":"Cannon","year":"1995","journal-title":"J. Dent. Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1128\/EC.00308-07","article-title":"Accidental virulence, cryptic pathogenesis, martians, lost hosts, and the pathogenicity of environmental microbes","volume":"6","author":"Casadevall","year":"2007","journal-title":"Eukaryot. Cell"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1086\/510677","article-title":"Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts","volume":"44","author":"Segal","year":"2007","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1128\/CMR.00029-06","article-title":"Epidemiology of invasive candidiasis: A persistent public health problem","volume":"20","author":"Pfaller","year":"2007","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s10096-007-0448-4","article-title":"A first Portuguese epidemiological survey of fungaemia in a university hospital","volume":"27","author":"Mendonca","year":"2008","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis. Off. Publ. Eur. Soc. Clin. Microbiol."},{"key":"ref_7","first-page":"661","article-title":"Candidemia in intensive care unit: A nationwide prospective observational survey (GISIA-3 study) and review of the European literature from 2000 through 2013","volume":"18","author":"Montagna","year":"2014","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.riam.2013.10.001","article-title":"Epidemiology of candidaemia and invasive candidiasis. A changing face","volume":"31","author":"Quindos","year":"2014","journal-title":"Rev. Iberoam. Micol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"18026","DOI":"10.1038\/nrdp.2018.26","article-title":"Invasive candidiasis","volume":"4","author":"Pappas","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s10096-007-0316-2","article-title":"Candidemia in immunocompromised and immunocompetent critically ill patients: A prospective comparative study","volume":"26","author":"Dimopoulos","year":"2007","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis. Off. Publ. Eur. Soc. Clin. Microbiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1086\/321811","article-title":"Risk factors for candidal bloodstream infections in surgical intensive care unit patients: The NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey","volume":"33","author":"Blumberg","year":"2001","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s001340050286","article-title":"Candidemia in non-neutropenic critically ill patients: Analysis of prognostic factors and assessment of systemic antifungal therapy. Study Group of Fungal Infection in the ICU","volume":"23","year":"1997","journal-title":"Intensive Care Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1086\/504810","article-title":"Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: A multi-institutional study","volume":"43","author":"Garey","year":"2006","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1086\/596757","article-title":"Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America","volume":"48","author":"Pappas","year":"2009","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1128\/AAC.49.8.3264-3273.2005","article-title":"Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates","volume":"49","author":"Park","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1517\/13543784.12.8.1313","article-title":"The echinocandin antifungals: An overview of the pharmacology, spectrum and clinical efficacy","volume":"12","author":"Wiederhold","year":"2003","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.diagmicrobio.2003.10.003","article-title":"The role of antifungal susceptibility testing in the therapy of candidiasis","volume":"48","author":"Hospenthal","year":"2004","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Costa-de-Oliveira, S., Araujo, R., Silva-Dias, A., Pina-Vaz, C., and Rodrigues, A.G. (2008). Propofol lipidic infusion promotes resistance to antifungals by reducing drug input into the fungal cell. BMC Microbiol., 8.","DOI":"10.1186\/1471-2180-8-9"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1080\/13693780500129814","article-title":"Human albumin promotes germination, hyphal growth and antifungal resistance by Aspergillus fumigatus","volume":"43","author":"Rodrigues","year":"2005","journal-title":"Med. Mycol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/TA.0b013e3181f2d4fb","article-title":"Candidemia in burn patients: Figures and facts","volume":"70","author":"Pedrosa","year":"2011","journal-title":"J. Trauma Acute Care Surg."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jinf.2006.11.017","article-title":"Risk of resistance associated with fluconazole prophylaxis: Systematic review","volume":"54","author":"Brion","year":"2007","journal-title":"J. Infect."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1086\/524071","article-title":"Antimicrobial resistance: Resistance to antifungal agents: Mechanisms and clinical impact","volume":"46","author":"Kanafani","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1586\/eri.09.18","article-title":"Antifungal drug resistance mechanisms","volume":"7","author":"Peman","year":"2009","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/jac\/dkq479","article-title":"Management of invasive fungal infections: A role for polyenes","volume":"66","author":"Chandrasekar","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"F429","DOI":"10.1136\/adc.2008.157123","article-title":"Oral nystatin prophylaxis and neonatal fungal infections","volume":"94","author":"Howell","year":"2009","journal-title":"Arch. Dis. Child. Fetal Neonatal Ed."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Gotzsche, P.C., and Johansen, H.K. (2002). Nystatin prophylaxis and treatment in severely immunodepressed patients. Cochrane Database Syst. Rev.","DOI":"10.1002\/14651858.CD002033"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1007\/s40261-012-0023-3","article-title":"Diagnosis and treatment of invasive fungal infections focus on liposomal amphotericin B","volume":"33","author":"Lacerda","year":"2013","journal-title":"Clin. Drug Investig."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1086\/317451","article-title":"A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph\/ABLC Collaborative Study Group","volume":"31","author":"Wingard","year":"2000","journal-title":"Clin. Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0014-5793(96)01360-9","article-title":"Resistance to fluconazole and cross-resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol delta5,6-desaturation","volume":"400","author":"Kelly","year":"1997","journal-title":"FEBS Lett."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/infdis\/154.1.76","article-title":"Amphotericin B-induced oxidative damage and killing of Candida albicans","volume":"154","author":"Brajtburg","year":"1986","journal-title":"J. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Castanheira, M., Deshpande, L.M., Davis, A.P., Rhomberg, P.R., and Pfaller, M.A. (2017). Monitoring Antifungal Resistance in a Global Collection of Invasive Yeasts and Molds: Application of CLSI Epidemiological Cutoff Values and Whole-Genome Sequencing Analysis for Detection of Azole Resistance in Candida albicans. Antimicrob. Agents Chemother., 61.","DOI":"10.1128\/AAC.00906-17"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/1469-0691.12513","article-title":"Update on antifungal resistance in Aspergillus and Candida","volume":"20","author":"Arendrup","year":"2014","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1007\/s10096-014-2194-8","article-title":"Species distribution and in vitro antifungal susceptibility profiles of yeast isolates from invasive infections during a Portuguese multicenter survey","volume":"33","author":"Ricardo","year":"2014","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/13693780500138971","article-title":"An update on antifungal targets and mechanisms of resistance in Candida albicans","volume":"43","author":"Akins","year":"2005","journal-title":"Med. Mycol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1128\/AAC.48.2.568-574.2004","article-title":"Three-dimensional models of wild-type and mutated forms of cytochrome P450 14alpha-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding","volume":"48","author":"Xiao","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0966-842X(03)00117-3","article-title":"Antifungal agents: Mechanisms of action","volume":"11","author":"Odds","year":"2003","journal-title":"Trends Microbiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1093\/jac\/dkm255","article-title":"Antifungal use in intensive care units","volume":"60","author":"Meyer","year":"2007","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1128\/JCM.00536-10","article-title":"Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document)","volume":"48","author":"Diekema","year":"2010","journal-title":"J. Clin. Microbiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1086\/523576","article-title":"Reviews of anti-infective agents: Posaconazole: A broad-spectrum triazole antifungal agent","volume":"45","author":"Nagappan","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1128\/JCM.00863-13","article-title":"In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds","volume":"51","author":"Pfaller","year":"2013","journal-title":"J. Clin. Microbiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1586\/14787210.2015.990382","article-title":"Isavuconazole, a broad-spectrum triazole for the treatment of systemic fungal diseases","volume":"13","author":"Seyedmousavi","year":"2015","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/jac\/dkp138","article-title":"In vitro activity of isavuconazole against Trichosporon, Rhodotorula, Geotrichum, Saccharomyces and Pichia species","volume":"64","author":"Thompson","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: Executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1128\/AAC.00463-08","article-title":"ABC transporter Cdr1p contributes more than Cdr2p does to fluconazole efflux in fluconazole-resistant Candida albicans clinical isolates","volume":"52","author":"Holmes","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1128\/AAC.47.4.1220-1227.2003","article-title":"Genome-wide expression profile analysis reveals coordinately regulated genes associated with stepwise acquisition of azole resistance in Candida albicans clinical isolates","volume":"47","author":"Rogers","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1016\/S0924-8579(08)70010-4","article-title":"Clinical relevance of resistance to antifungals","volume":"32","author":"Cuesta","year":"2008","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/00001432-200212000-00003","article-title":"Recent trends in the epidemiology of invasive mycoses","volume":"15","author":"Clark","year":"2002","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_49","first-page":"259","article-title":"Candida krusei reservoir in a neutropaenia unit: Molecular evidence of a foe?","volume":"17","author":"Ricardo","year":"2011","journal-title":"Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1093\/clinids\/22.Supplement_2.S73","article-title":"The role of the gastrointestinal tract in hematogenous candidiasis: From the laboratory to the bedside","volume":"22","author":"Cole","year":"1996","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1128\/AAC.43.11.2753","article-title":"The ATP binding cassette transporter gene CgCDR1 from Candida glabrata is involved in the resistance of clinical isolates to azole antifungal agents","volume":"43","author":"Sanglard","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nrmicro1835","article-title":"The evolution of fungal drug resistance: Modulating the trajectory from genotype to phenotype","volume":"6","author":"Cowen","year":"2008","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/j.1567-1364.2009.00578.x","article-title":"Antifungal drug resistance mechanisms in fungal pathogens from the perspective of transcriptional gene regulation","volume":"9","author":"Sanglard","year":"2009","journal-title":"FEMS Yeast Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1093\/jnci\/92.16.1295","article-title":"A family of drug transporters: The multidrug resistance-associated proteins","volume":"92","author":"Borst","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.fgb.2009.08.002","article-title":"Regulation of multidrug resistance in pathogenic fungi","volume":"47","author":"Morschhauser","year":"2010","journal-title":"Fungal Genet. Biol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1128\/CMR.00051-08","article-title":"Efflux-mediated antifungal drug resistance","volume":"22","author":"Cannon","year":"2009","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1128\/AAC.42.12.3065","article-title":"Multiple molecular mechanisms contribute to a stepwise development of fluconazole resistance in clinical Candida albicans strains","volume":"42","author":"Franz","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1128\/AAC.45.10.2676-2684.2001","article-title":"Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients","volume":"45","author":"Perea","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/j.1567-1364.2009.00504.x","article-title":"Ibuprofen reverts antifungal resistance on Candida albicans showing overexpression of CDR genes","volume":"9","author":"Ricardo","year":"2009","journal-title":"FEMS Yeast Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1128\/EC.00137-15","article-title":"The ABCs of Candida albicans Multidrug Transporter Cdr1","volume":"14","author":"Prasad","year":"2015","journal-title":"Eukaryot. Cell"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1128\/EC.3.6.1639-1652.2004","article-title":"TAC1, transcriptional activator of CDR genes, is a new transcription factor involved in the regulation of Candida albicans ABC transporters CDR1 and CDR2","volume":"3","author":"Coste","year":"2004","journal-title":"Eukaryot. Cell"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1534\/genetics.105.054767","article-title":"A mutation in Tac1p, a transcription factor regulating CDR1 and CDR2, is coupled with loss of heterozygosity at chromosome 5 to mediate antifungal resistance in Candida albicans","volume":"172","author":"Coste","year":"2006","journal-title":"Genetics"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1126\/science.1128242","article-title":"Aneuploidy and isochromosome formation in drug-resistant Candida albicans","volume":"313","author":"Selmecki","year":"2006","journal-title":"Science"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1111\/j.1365-2958.2004.04068.x","article-title":"Homozygosity at the MTL locus in clinical strains of Candida albicans: Karyotypic rearrangements and tetraploid formation","volume":"52","author":"Legrand","year":"2004","journal-title":"Mol. Microbiol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1126\/science.285.5431.1271","article-title":"Identification of a mating type-like locus in the asexual pathogenic yeast Candida albicans","volume":"285","author":"Hull","year":"1999","journal-title":"Science"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1128\/EC.00151-07","article-title":"Genotypic evolution of azole resistance mechanisms in sequential Candida albicans isolates","volume":"6","author":"Coste","year":"2007","journal-title":"Eukaryot. Cell"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1099\/00221287-148-4-1061","article-title":"Homozygosity at the Candida albicans MTL locus associated with azole resistance","volume":"148","author":"Rustad","year":"2002","journal-title":"Microbiology"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/genetics\/162.2.737","article-title":"In Candida albicans, white-opaque switchers are homozygous for mating type","volume":"162","author":"Lockhart","year":"2002","journal-title":"Genetics"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1128\/AAC.47.4.1207-1212.2003","article-title":"Drug resistance is not directly affected by mating type locus zygosity in Candida albicans","volume":"47","author":"Pujol","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1128\/AAC.46.6.1704-1713.2002","article-title":"Resistance mechanisms in clinical isolates of Candida albicans","volume":"46","author":"White","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Morschhauser, J., Barker, K.S., Liu, T.T., Bla, B.W.J., Homayouni, R., and Rogers, P.D. (2007). The transcription factor Mrr1p controls expression of the MDR1 efflux pump and mediates multidrug resistance in Candida albicans. PLoS Pathog., 3.","DOI":"10.1371\/journal.ppat.0030164"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1111\/j.1365-2958.2008.06309.x","article-title":"Mutations in the multi-drug resistance regulator MRR1, followed by loss of heterozygosity, are the main cause of MDR1 overexpression in fluconazole-resistant Candida albicans strains","volume":"69","author":"Dunkel","year":"2008","journal-title":"Mol. Microbiol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1128\/AAC.42.2.241","article-title":"Amino acid substitutions in the cytochrome P-450 lanosterol 14alpha-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents","volume":"42","author":"Sanglard","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1128\/AAC.47.8.2404-2412.2003","article-title":"Candida albicans mutations in the ergosterol biosynthetic pathway and resistance to several antifungal agents","volume":"47","author":"Sanglard","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/jac\/49.3.515","article-title":"Heterogeneous mechanisms of azole resistance in Candida albicans clinical isolates from an HIV-infected patient on continuous fluconazole therapy for oropharyngeal candidosis","volume":"49","author":"Martinez","year":"2002","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/j.1365-2958.2008.06176.x","article-title":"An isochromosome confers drug resistance in vivo by amplification of two genes, ERG11 and TAC1","volume":"68","author":"Selmecki","year":"2008","journal-title":"Mol. Microbiol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1128\/EC.3.6.1391-1397.2004","article-title":"Role of Candida albicans transcription factor Upc2p in drug resistance and sterol metabolism","volume":"3","author":"Silver","year":"2004","journal-title":"Eukaryot. Cell"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1128\/EC.00103-08","article-title":"A gain-of-function mutation in the transcription factor Upc2p causes upregulation of ergosterol biosynthesis genes and increased fluconazole resistance in a clinical Candida albicans isolate","volume":"7","author":"Dunkel","year":"2008","journal-title":"Eukaryot. Cell"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1128\/AAC.01102-09","article-title":"An A643T mutation in the transcription factor Upc2p causes constitutive ERG11 upregulation and increased fluconazole resistance in Candida albicans","volume":"54","author":"Heilmann","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1128\/EC.00331-06","article-title":"cis-Acting elements within the Candida albicans ERG11 promoter mediate the azole response through transcription factor Upc2p","volume":"6","author":"Oliver","year":"2007","journal-title":"Eukaryot. Cell"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1128\/AAC.00995-10","article-title":"An A643V amino acid substitution in Upc2p contributes to azole resistance in well-characterized clinical isolates of Candida albicans","volume":"55","author":"Hoot","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"34998","DOI":"10.1074\/jbc.M306291200","article-title":"Genome-wide expression profiling of the response to polyene, pyrimidine, azole, and echinocandin antifungal agents in Saccharomyces cerevisiae","volume":"278","author":"Agarwal","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/S0140-6736(03)14472-8","article-title":"Echinocandin antifungal drugs","volume":"362","author":"Denning","year":"2003","journal-title":"Lancet"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.drup.2007.04.002","article-title":"Resistance to echinocandin-class antifungal drugs","volume":"10","author":"Perlin","year":"2007","journal-title":"Drug Resist. Updates"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1128\/AAC.01162-08","article-title":"Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: Implications for interpretive breakpoints","volume":"53","author":"Park","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1128\/AAC.00349-06","article-title":"Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility","volume":"50","author":"Katiyar","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1128\/AAC.00998-09","article-title":"Novel FKS mutations associated with echinocandin resistance in Candida species","volume":"54","author":"Chua","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1093\/ofid\/ofy358","article-title":"Twenty Years of the SENTRY Antifungal Surveillance Program: Results for Candida Species from 1997\u20132016","volume":"6","author":"Pfaller","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"e1211","DOI":"10.1016\/j.cmi.2018.05.012","article-title":"Accuracy of Sensititre YeastOne echinocandins epidemiological cut-off values for identification of FKS mutant Candida albicans and Candida glabrata: A ten year national survey of the Fungal Infection Network of Switzerland (FUNGINOS)","volume":"24","author":"Kritikos","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"3690","DOI":"10.1128\/AAC.00443-09","article-title":"Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: Implication for the existing susceptibility breakpoint","volume":"53","author":"Lee","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1128\/AAC.00105-07","article-title":"In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera","volume":"51","author":"Wiederhold","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1128\/AAC.01536-06","article-title":"Serum differentially alters the antifungal properties of echinocandin drugs","volume":"51","author":"Paderu","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.drup.2015.10.001","article-title":"Defining the frontiers between antifungal resistance, tolerance and the concept of persistence","volume":"23","author":"Delarze","year":"2015","journal-title":"Drug Resist. Updates"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1128\/CMR.00059-05","article-title":"Human pharmacogenomic variations and their implications for antifungal efficacy","volume":"19","author":"Meletiadis","year":"2006","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1128\/EC.00041-08","article-title":"Stress, drugs, and evolution: The role of cellular signaling in fungal drug resistance","volume":"7","author":"Cowen","year":"2008","journal-title":"Eukaryot. Cell"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1128\/AAC.47.10.3195-3201.2003","article-title":"Cyclic AMP signaling pathway modulates susceptibility of candida species and Saccharomyces cerevisiae to antifungal azoles and other sterol biosynthesis inhibitors","volume":"47","author":"Jain","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1091\/mbc.e04-09-0780","article-title":"The G protein-coupled receptor Gpr1 and the Galpha protein Gpa2 act through the cAMP-protein kinase A pathway to induce morphogenesis in Candida albicans","volume":"16","author":"Maidan","year":"2005","journal-title":"Mol. Biol. Cell"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1080\/21505594.2016.1201250","article-title":"Calcineurin in fungal virulence and drug resistance: Prospects for harnessing targeted inhibition of calcineurin for an antifungal therapeutic approach","volume":"8","author":"Juvvadi","year":"2017","journal-title":"Virulence"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"7330","DOI":"10.1128\/IAI.72.12.7330-7333.2004","article-title":"The calcineurin target, Crz1, functions in azole tolerance but is not required for virulence of Candida albicans","volume":"72","author":"Onyewu","year":"2004","journal-title":"Infect. Immun."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1046\/j.1365-2958.2003.03495.x","article-title":"Calcineurin A of Candida albicans: Involvement in antifungal tolerance, cell morphogenesis and virulence","volume":"48","author":"Sanglard","year":"2003","journal-title":"Mol. Microbiol."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Jia, Y., Tang, R.J., Wang, L., Zhang, X., Wang, Y., Jia, X.M., and Jiang, Y.Y. (2012). Calcium-activated-calcineurin reduces the In vitro and In vivo sensitivity of fluconazole to Candida albicans via Rta2p. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0048369"},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Singh, S.D., Robbins, N., Zaas, A.K., Schell, W.A., Perfect, J.R., and Cowen, L.E. (2009). Hsp90 governs echinocandin resistance in the pathogenic yeast Candida albicans via calcineurin. PLoS Pathog., 5.","DOI":"10.1371\/journal.ppat.1000532"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Walker, L.A., Munro, C.A., de Bruijn, I., Lenardon, M.D., McKinnon, A., and Gow, N.A. (2008). Stimulation of chitin synthesis rescues Candida albicans from echinocandins. PLoS Pathog., 4.","DOI":"10.1371\/journal.ppat.1000040"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1111\/j.1365-2958.2007.05588.x","article-title":"The PKC, HOG and Ca2+ signalling pathways co-ordinately regulate chitin synthesis in Candida albicans","volume":"63","author":"Munro","year":"2007","journal-title":"Mol. Microbiol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.mib.2010.05.002","article-title":"Chitin synthesis and fungal pathogenesis","volume":"13","author":"Lenardon","year":"2010","journal-title":"Curr. Opin. Microbiol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1128\/AAC.00563-06","article-title":"Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for beta-1,6-glucan synthesis inhibition by caspofungin","volume":"50","author":"Stevens","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1128\/AAC.01525-06","article-title":"Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro","volume":"51","author":"Jacobsen","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s10096-007-0411-4","article-title":"Paradoxical growth effects of the echinocandins caspofungin and micafungin, but not of anidulafungin, on clinical isolates of Candida albicans and C. dubliniensis","volume":"27","author":"Fleischhacker","year":"2008","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1128\/AAC.01486-12","article-title":"Elevated chitin content reduces the susceptibility of Candida species to caspofungin","volume":"57","author":"Walker","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_110","first-page":"324","article-title":"Determination of chitin content in fungal cell wall: An alternative flow cytometric method","volume":"83","author":"Silva","year":"2013","journal-title":"Cytom. Part"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1128\/AAC.00683-11","article-title":"Elevated Cell Wall Chitin in Candida albicans Confers Echinocandin Resistance In Vivo","volume":"56","author":"Lee","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1128\/AAC.00999-10","article-title":"Paradoxical effect of caspofungin against Candida bloodstream isolates is mediated by multiple pathways but eliminated in human serum","volume":"55","author":"Shields","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41467-017-00547-y","article-title":"The Candida albicans transcription factor Cas5 couples stress responses, drug resistance and cell cycle regulation","volume":"8","author":"Xie","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"5026","DOI":"10.1128\/AAC.00516-13","article-title":"Chromosome 5 monosomy of Candida albicans controls susceptibility to various toxic agents, including major antifungals","volume":"57","author":"Yang","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Yang, F., Zhang, L., Wakabayashi, H., Myers, J., Jiang, Y., Cao, Y., Jimenez-Ortigosa, C., Perlin, D.S., and Rustchenko, E. (2017). Tolerance to Caspofungin in Candida albicans Is Associated with at Least Three Distinctive Mechanisms That Govern Expression of FKS Genes and Cell Wall Remodeling. Antimicrob. Agents Chemother., 61.","DOI":"10.1128\/AAC.00071-17"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"7457","DOI":"10.1128\/AAC.01888-16","article-title":"Chromosome 5 of Human Pathogen Candida albicans Carries Multiple Genes for Negative Control of Caspofungin and Anidulafungin Susceptibility","volume":"60","author":"Suwunnakorn","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1128\/AAC.02408-13","article-title":"Macrophage reporter cell assay for screening immunopharmacological activity of cell wall-active antifungals","volume":"58","author":"Lewis","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1128\/IAI.01282-10","article-title":"Recognition and blocking of innate immunity cells by Candida albicans chitin","volume":"79","author":"Netea","year":"2011","journal-title":"Infect. Immun."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Marakalala, M.J., Vautier, S., Potrykus, J., Walker, L.A., Shepardson, K.M., Hopke, A., Mora-Montes, H.M., Kerrigan, A., Netea, M.G., and Murray, G.I. (2013). Differential adaptation of Candida albicans in vivo modulates immune recognition by dectin-1. PLoS Pathog., 9.","DOI":"10.1371\/annotation\/7821bda1-dde3-4e72-b688-447b6bca20ea"},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Miranda, I., Rocha, R., Santos, M.C., Mateus, D.D., Moura, G.R., Carreto, L., and Santos, M.A. (2007). A genetic code alteration is a phenotype diversity generator in the human pathogen Candida albicans. PLoS ONE, 2.","DOI":"10.1371\/journal.pone.0000996"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1038\/sj.emboj.7601876","article-title":"Critical roles for a genetic code alteration in the evolution of the genus Candida","volume":"26","author":"Silva","year":"2007","journal-title":"EMBO J."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.mib.2009.05.008","article-title":"Hidden killers: Persistence of opportunistic fungal pathogens in the human host","volume":"12","year":"2009","journal-title":"Curr. Opin. Microbiol."},{"key":"ref_123","first-page":"205","article-title":"Adhesion, biofilm formation, cell surface hydrophobicity, and antifungal planktonic susceptibility: Relationship among Candida spp.","volume":"6","author":"Miranda","year":"2015","journal-title":"Front. Microbiol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.tim.2016.09.004","article-title":"Portrait of Candida Species Biofilm Regulatory Network Genes","volume":"25","author":"Araujo","year":"2017","journal-title":"Trends Microbiol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.cell.2011.10.048","article-title":"A recently evolved transcriptional network controls biofilm development in Candida albicans","volume":"148","author":"Nobile","year":"2012","journal-title":"Cell"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"6023","DOI":"10.1128\/IAI.72.10.6023-6031.2004","article-title":"Development and characterization of an in vivo central venous catheter Candida albicans biofilm model","volume":"72","author":"Andes","year":"2004","journal-title":"Infect. Immun."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"4333","DOI":"10.1128\/IAI.71.8.4333-4340.2003","article-title":"Mechanism of fluconazole resistance in Candida albicans biofilms: Phase-specific role of efflux pumps and membrane sterols","volume":"71","author":"Mukherjee","year":"2003","journal-title":"Infect. Immun."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"528521","DOI":"10.1155\/2012\/528521","article-title":"Fungal biofilm resistance","volume":"2012","author":"Ramage","year":"2012","journal-title":"Int. J. Microbiol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/jac\/dkf049","article-title":"Investigation of multidrug efflux pumps in relation to fluconazole resistance in Candida albicans biofilms","volume":"49","author":"Ramage","year":"2002","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s10096-014-2287-4","article-title":"Efficacy and safety of echinocandins versus triazoles for the prophylaxis and treatment of fungal infections: A Meta-analysis of RCTs","volume":"34","author":"Wang","year":"2015","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"S622","DOI":"10.1093\/cid\/civ746","article-title":"Role of Echinocandins in Fungal Biofilm-Related Disease: Vascular Catheter-Related Infections, Immunomodulation, and Mucosal Surfaces","volume":"61","author":"Katragkou","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/j.1567-1364.2010.00618.x","article-title":"Liposomal amphotericin B eradicates Candida albicans biofilm in a continuous catheter flow model","volume":"10","author":"Seidler","year":"2010","journal-title":"FEMS Yeast Res."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"i73","DOI":"10.1093\/jac\/dkx451","article-title":"Biofilms and beyond: Expanding echinocandin utility","volume":"73","author":"Larkin","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1128\/AAC.47.3.847-853.2003","article-title":"Relationships between respiration and susceptibility to azole antifungals in Candida glabrata","volume":"47","author":"Brun","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1128\/AAC.50.2.744-747.2006","article-title":"Inhibition of Candida parapsilosis mitochondrial respiratory pathways enhances susceptibility to caspofungin","volume":"50","author":"Chamilos","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/j.1567-1364.2012.00789.x","article-title":"An alternative respiratory pathway on Candida krusei: Implications on susceptibility profile and oxidative stress","volume":"12","author":"Barbosa","year":"2012","journal-title":"FEMS Yeast Res."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1093\/jac\/dkp273","article-title":"The alternative oxidase of Candida albicans causes reduced fluconazole susceptibility","volume":"64","author":"Yan","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.1099\/mic.0.2007\/010405-0","article-title":"Candida albicans drug resistance another way to cope with stress","volume":"153","author":"Cannon","year":"2007","journal-title":"Microbiology"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00294-019-01001-w","article-title":"The potential of respiration inhibition as a new approach to combat human fungal pathogens","volume":"65","author":"Duvenage","year":"2019","journal-title":"Curr. Genet."},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Duvenage, L., Walker, L.A., Bojarczuk, A., Johnston, S.A., MacCallum, D.M., Munro, C.A., and Gourlay, C.W. (2019). Inhibition of Classical and Alternative Modes of Respiration in Candida albicans Leads to Cell Wall Remodeling and Increased Macrophage Recognition. MBio, 10.","DOI":"10.1128\/mBio.02535-18"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S1473-3099(03)00831-4","article-title":"Management of Candida species infections in critically ill patients","volume":"3","author":"Eggimann","year":"2003","journal-title":"Lancet Infect. Dis."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1002\/cncr.23466","article-title":"The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy","volume":"112","author":"Hachem","year":"2008","journal-title":"Cancer"},{"key":"ref_143","first-page":"267","article-title":"Central venous catheter infection with Rhodotorula minuta in a patient with AIDS taking suppressive doses of fluconazole","volume":"33","author":"Goldani","year":"1995","journal-title":"J. Med. Vet. Mycol. Bi-Mon. Publ. Int. Soc. Hum. Anim. Mycol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1146\/annurev.mi.45.100191.001155","article-title":"Putative virulence factors of Candida albicans","volume":"45","author":"Cutler","year":"1991","journal-title":"Annu. Rev. Microbiol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1093\/jac\/dkm513","article-title":"Rifampicin induces MDR1 expression in Candida albicans","volume":"61","author":"Vogel","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1093\/jac\/dkn473","article-title":"Comparative pharmacodynamic interaction analysis between ciprofloxacin, moxifloxacin and levofloxacin and antifungal agents against Candida albicans and Aspergillus fumigatus","volume":"63","author":"Stergiopoulou","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Nogueira, F., Sharghi, S., Kuchler, K., and Lion, T. (2019). Pathogenetic Impact of Bacterial-Fungal Interactions. Microorganisms, 7.","DOI":"10.3390\/microorganisms7100459"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1021\/bi0521745","article-title":"Modulator-induced interference in functional cross talk between the substrate and the ATP sites of human P-glycoprotein","volume":"45","author":"Maki","year":"2006","journal-title":"Biochemistry"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.coph.2006.01.009","article-title":"Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer","volume":"6","author":"Modok","year":"2006","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1136\/ard.2007.070821","article-title":"Overcoming drug resistance induced by P-glycoprotein on lymphocytes in patients with refractory rheumatoid arthritis","volume":"67","author":"Tsujimura","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/1567-1364.12149","article-title":"FK520 interacts with the discrete intrahelical amino acids of multidrug transporter Cdr1 protein and acts as antagonist to selectively chemosensitize azole-resistant clinical isolates of Candida albicans","volume":"14","author":"Nim","year":"2014","journal-title":"FEMS Yeast Res."},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Tanabe, K., Bonus, M., Tomiyama, S., Miyoshi, K., Nagi, M., Niimi, K., Chindamporn, A., Gohlke, H., Schmitt, L., and Cannon, R.D. (2019). FK506 Resistance of Saccharomyces cerevisiae Pdr5 and Candida albicans Cdr1 Involves Mutations in the Transmembrane Domains and Extracellular Loops. Antimicrob. Agents Chemother., 63.","DOI":"10.1128\/AAC.01146-18"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0006-2952(92)90668-9","article-title":"Cyclosporins as drug resistance modifiers","volume":"43","author":"Twentyman","year":"1992","journal-title":"Biochem. Pharmacol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"15463","DOI":"10.1074\/jbc.270.26.15463","article-title":"Interaction of FKBP12-FK506 with calcineurin A at the B subunit-binding domain","volume":"270","author":"Kawamura","year":"1995","journal-title":"J. Biol. Chem."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1128\/AAC.01070-07","article-title":"In vitro interactions between tacrolimus and azoles against Candida albicans determined by different methods","volume":"52","author":"Sun","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1128\/AAC.44.11.2932-2938.2000","article-title":"Fluconazole plus cyclosporine: A fungicidal combination effective against experimental endocarditis due to Candida albicans","volume":"44","author":"Marchetti","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/nrmicro1680","article-title":"Harnessing calcineurin as a novel anti-infective agent against invasive fungal infections","volume":"5","author":"Steinbach","year":"2007","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/jac\/dkl486","article-title":"Aspirin and ibuprofen enhance pyrazinamide treatment of murine tuberculosis","volume":"59","author":"Byrne","year":"2007","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1439-0507.2004.01052.x","article-title":"Reassessment of the in vitro synergistic effect of fluconazole with the non-steroidal anti-inflammatory agent ibuprofen against Candida albicans","volume":"48","author":"Arai","year":"2005","journal-title":"Mycoses"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1093\/jac\/dki264","article-title":"Potent synergic effect between ibuprofen and azoles on Candida resulting from blockade of efflux pumps as determined by FUN-1 staining and flow cytometry","volume":"56","author":"Rodrigues","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.diagmicrobio.2011.05.007","article-title":"In vitro synergisms obtained by amphotericin B and voriconazole associated with non-antifungal agents against Fusarium spp.","volume":"71","author":"Venturini","year":"2011","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"4289","DOI":"10.1128\/AAC.05056-14","article-title":"Ibuprofen potentiates the in vivo antifungal activity of fluconazole against Candida albicans murine infection","volume":"59","author":"Miranda","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3109\/13880209.2015.1091483","article-title":"The roles of CDR1, CDR2, and MDR1 in kaempferol-induced suppression with fluconazole-resistant Candida albicans","volume":"54","author":"Shao","year":"2016","journal-title":"Pharm. Biol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1128\/AAC.49.1.57-70.2005","article-title":"Surface-active fungicidal D-peptide inhibitors of the plasma membrane proton pump that block azole resistance","volume":"49","author":"Monk","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"12128","DOI":"10.1073\/pnas.0805374105","article-title":"Overcoming multidrug resistance of small-molecule therapeutics through conjugation with releasable octaarginine transporters","volume":"105","author":"Dubikovskaya","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/j.1469-0691.2004.00996.x","article-title":"In-vitro activity of nikkomycin Z alone and in combination with polyenes, triazoles or echinocandins against Aspergillus fumigatus","volume":"10","author":"Ganesan","year":"2004","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1128\/AAC.44.9.2547-2548.2000","article-title":"Drug interaction studies of a glucan synthase inhibitor (LY 303366) and a chitin synthase inhibitor (Nikkomycin Z) for inhibition and killing of fungal pathogens","volume":"44","author":"Stevens","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1128\/AAC.05323-11","article-title":"Reshuffling of Aspergillus fumigatus cell wall components chitin and beta-glucan under the influence of caspofungin or nikkomycin Z alone or in combination","volume":"56","author":"Verwer","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1128\/AAC.02647-13","article-title":"Modulation of Alternaria infectoria cell wall chitin and glucan synthesis by cell wall synthase inhibitors","volume":"58","author":"Fernandes","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/lam.13204","article-title":"Synergistic effect of nikkomycin Z with caspofungin and micafungin against Candida albicans and Candida parapsilosis biofilms","volume":"69","author":"Kovacs","year":"2019","journal-title":"Lett. Appl. Microbiol."},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"Cheung, Y.Y., and Hui, M. (2017). Effects of Echinocandins in Combination with Nikkomycin Z against Invasive Candida albicans Bloodstream Isolates and the fks Mutants. Antimicrob. Agents Chemother., 61.","DOI":"10.1128\/AAC.00619-17"}],"container-title":["Microorganisms"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-2607\/8\/2\/154\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:20:34Z","timestamp":1760361634000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-2607\/8\/2\/154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,22]]},"references-count":171,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,2]]}},"alternative-id":["microorganisms8020154"],"URL":"https:\/\/doi.org\/10.3390\/microorganisms8020154","relation":{},"ISSN":["2076-2607"],"issn-type":[{"value":"2076-2607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,22]]}}}